Qingdao Haier Biomedical Co Ltd (SHG:688139) — Market Cap & Net Worth
Market Cap & Net Worth: Qingdao Haier Biomedical Co Ltd (688139)
Qingdao Haier Biomedical Co Ltd (SHG:688139) has a market capitalization of $1.46 Billion (CN¥9.99 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #7530 globally and #1832 in its home market, demonstrating a -6.07% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Qingdao Haier Biomedical Co Ltd's stock price CN¥31.56 by its total outstanding shares 316492922 (316.49 Million). Analyse cash flow conversion of Qingdao Haier Biomedical Co Ltd to see how efficiently the company converts income to cash.
Qingdao Haier Biomedical Co Ltd Market Cap History: 2019 to 2026
Qingdao Haier Biomedical Co Ltd's market capitalization history from 2019 to 2026. Data shows growth from $1.31 Billion to $1.46 Billion (0.90% CAGR).
Qingdao Haier Biomedical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Qingdao Haier Biomedical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.63x
Qingdao Haier Biomedical Co Ltd's market cap is 0.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.87x
Qingdao Haier Biomedical Co Ltd's market cap is 5.87 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.31 Billion | $1.01 Billion | $182.06 Million | 1.29x | 7.18x |
| 2020 | $2.97 Billion | $1.40 Billion | $380.95 Million | 2.12x | 7.79x |
| 2021 | $4.14 Billion | $2.13 Billion | $845.04 Million | 1.95x | 4.90x |
| 2022 | $2.91 Billion | $2.86 Billion | $600.79 Million | 1.02x | 4.84x |
| 2023 | $1.88 Billion | $2.28 Billion | $406.07 Million | 0.82x | 4.62x |
| 2024 | $1.63 Billion | $2.28 Billion | $366.63 Million | 0.71x | 4.45x |
| 2025 | $1.47 Billion | $2.33 Billion | $250.73 Million | 0.63x | 5.87x |
Competitor Companies of 688139 by Market Capitalization
Companies near Qingdao Haier Biomedical Co Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to Qingdao Haier Biomedical Co Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #151 globally with a market cap of $150.06 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #211 globally with a market cap of $111.87 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (XETRA:2M6): Ranked #246 globally with a market cap of $99.67 Billion USD ( €85.25 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #151 | Abbott Laboratories | NYSE:ABT | $150.06 Billion | $86.30 |
| #211 | Stryker Corporation | NYSE:SYK | $111.87 Billion | $292.33 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #246 | Medtronic PLC | XETRA:2M6 | $99.67 Billion | €66.40 |
Qingdao Haier Biomedical Co Ltd Historical Marketcap From 2019 to 2026
Between 2019 and today, Qingdao Haier Biomedical Co Ltd's market cap moved from $1.31 Billion to $ 1.46 Billion, with a yearly change of 0.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.46 Billion | -0.69% |
| 2025 | CN¥1.47 Billion | -9.72% |
| 2024 | CN¥1.63 Billion | -13.13% |
| 2023 | CN¥1.88 Billion | -35.46% |
| 2022 | CN¥2.91 Billion | -29.83% |
| 2021 | CN¥4.14 Billion | +39.63% |
| 2020 | CN¥2.97 Billion | +127.10% |
| 2019 | CN¥1.31 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Qingdao Haier Biomedical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.46 Billion USD |
| MoneyControl | $1.46 Billion USD |
| MarketWatch | $1.46 Billion USD |
| marketcap.company | $1.46 Billion USD |
| Reuters | $1.46 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Qingdao Haier Biomedical Co Ltd
Qingdao Haier Biomedical Co.,Ltd engages in the research and development, manufacture, marketing, and sale of low temperature storage equipment for biomedical samples in China and internationally. The company offers ULT freezers, pharmacy refrigerators, freezers, automatic storage solutions, cryogenics, active temperature controlled RKN containers, and RTMD products; and CO2 incubation, standard … Read more